Table 4:

Summary of categories contributing to the cumulative cost and utility from deterministic analysis of the base model comparing rituximab to cyclosporine for the treatment of primary membranous nephropathy.

	Value
Category	Rituximab	Cyclosporine
Cost categories ($)
Drug cost (%)	46 543 (60.8)	8257 (17.0)
Dialysis cost (%)	29 046 (38.0)	39 049 (80.5)
Transplant cost (%)	936 (0.2)	1212 (2.5)
Total	76 525	48 518
Utility categories (QALYs)
On treatment (%)	0.90 (6.5)	2.59 (12.2)
CR (%)	6.29 (45.2)	0.091 (0.4)
PR (%)	3.55 (25.5)	7.73 (36.5)
NR (%)	2.94 (21.1)	10.09 (47.6)
Dialysis (%)	0.25 (1.8)	0.66 (3.1)
Transplant (%)	0.007 (<0.1)	0.018 (<0.1)
Total	13.94	21.18